New combo therapy shows promise for blinding eye condition
NCT ID NCT03941587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two treatments for polypoidal choroidal vasculopathy (PCV), an eye disease that can lead to blindness. Sixty patients received either eye injections of aflibercept alone or aflibercept combined with a special light therapy (reduced-fluence PDT). The goal was to see which approach better closed abnormal blood vessels and improved vision over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore
-
Singapore National Eye Centre
Singapore, Singapore, 168751, Singapore